WinstonWınston
Escalon Medical logo

Escalon Medical

ESMC
29
Medical - Devices · Healthcare
Price
$0.20
+0.02 (+9.29%)
Market Cap
$1.5M
Winston Score
29
Winston is worried
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+92.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.4M (2021) → 14.3M (2025)

Escalon Medical Corp. makes medical devices and supplies used by eye doctors and hospitals. Its main products include equipment for eye surgery, ultrasound imaging tools for the eye, and related consumable supplies. The company sells primarily to ophthalmologists, eye clinics, and surgical centers in the United States and some international markets.

Escalon earns revenue by selling its devices outright and through ongoing sales of disposable supplies that customers need to keep using the equipment. It is a small company, with a market cap under $100 million, and competes against much larger medical device makers like Alcon and Bausch + Lomb. The company currently operates at a loss, as shown by its negative operating and return margins, which means its costs exceed what it brings in — the main risk is whether it can grow sales fast enough to reach consistent profitability in a market dominated by well-funded competitors.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-26.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-268.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$753M/ year

Rising (+109337% vs prior year)

>1,000% of revenue

347.3x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

1.9%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$545,835 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Escalon Medical is putting 6252% of revenue into R&D and that number is rising. That's 347.3x the sector average. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
43.7%
Healthy — 43.7% gross margin
Operating Margin
-14.5%
Losing money on operations — -14.5%
ROCE
-17.0%
Weak — -17.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+21963.6%
Fast-growing sales (21963.6% YoY)
EPS YoY
-428.4%
Earnings shrinking (-428.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-16.1%
Burning cash (-16.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.14
Conservative — low debt load (0.14)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
1.8x
Attractive valuation — P/E 1.8

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial